Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1930631 | 0.87 | PKM (0.61) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL1932281 | 0.84 | PKM (0.65) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL2741402 | 0.83 | PKM (0.64) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL8203532 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL699639 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3303527 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL4537086 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL10724066 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL565301 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A | |
| SCHEMBL3971438 | 0.83 | PKM (0.88) | PKMHTTALDH1A1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115947761-B | Ruthenium carbene catalyst, composition containing ruthenium carbene catalyst, preparation method and application of ruthenium carbene catalyst | 上海中化科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12377407-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2025096300-A1 | NOVEL METHODS FOR THE PREPARATION OF 3-AZABICYLCO[3.1,0]HEXANE-6-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| CN-119930696-A | Imidazole coordinated ruthenium carbene olefin metathesis catalyst, preparation and application thereof | 中国石油天然气股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250042854-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | ECOLE NAT SUPERIEURE DE CHIMIE DE RENNES (FR) | 2025-02-06 | — | — | US | disclosed |
| WO-2025008012-A1 | PYRROLOQUINOLINES AND THEIR USE AS TUBULINE ASSEMBLY INHIBITORS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2025-01-09 | — | — | WO | disclosed |
| US-12139504-B2 | Vanadium alkylidene complex, synthesis and use thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-11-12 | — | — | US | disclosed |
| EP-4433451-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | Ecole Nationale Supérieure de Chimie de Rennes (FR) | 2024-09-25 | — | — | EP | disclosed |
| CN-109496214-B | Crystal form and salt form of nitroimidazole compound and preparation method thereof | 成都嘉葆药银医药科技有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20240228519-A1 | VANADIUM ALKYLIDENE COMPLEX, SYNTHESIS AND USE THEREOF | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-07-11 | — | — | US | disclosed |
| EP-1037897-A1 | HIGHLY ACTIVE CATIONIC RUTHENIUM AND OSMIUM COMPLEXES FOR OLEFIN METATHESIS REACTIONS | Studiengesellschaft Kohle mbH (DE) | 2000-09-27 | — | — | EP | disclosed |
| EP-0975622-A1 | SELECTIVE OLEFIN METATHESIS OF BIFUNCTIONAL OR POLYFUNCTIONAL SUBSTRATES IN COMPRESSED CARBON DIOXIDE AS REACTION MEDIUM | Studiengesellschaft Kohle mbH (DE) | 2000-02-02 | — | — | EP | disclosed |
| US-6004956-A | CHEMICAL INTERMEDIATES FOR BACTERICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-21 | — | — | US | disclosed |
| WO-1999028330-A1 | HIGHLY ACTIVE CATIONIC RUTHENIUM AND OSMIUM COMPLEXES FOR OLEFIN METATHESIS REACTIONS | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 1999-06-10 | — | — | WO | disclosed |
| EP-0921129-A1 | Highly active cationic ruthenium and osmium complexes for olefin metathesis reactions | Studiengesellschaft Kohle mbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| EP-0551653-B1 | Enantiomeric pure cis-2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation | BAYER AG (DE) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998047891-A1 | SELECTIVE OLEFIN METATHESIS OF BIFUNCTIONAL OR POLYFUNCTIONAL SUBSTRATES IN COMPRESSED CARBON DIOXIDE AS REACTION MEDIUM | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 1998-10-29 | — | — | WO | disclosed |
| US-5532364-A | FROM A DIHYDROPYRIDINE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 1996-07-02 | — | — | US | disclosed |
| US-5436334-A | Enantiomerically pure 2-oxa-5,8-diazabicyclo[4.3.0]nonanes and process for their preparation | BAYER AKTIENGESELLSCHAFT (DE) | 1995-07-25 | — | — | US | disclosed |
| EP-0551653-A1 | Enantiomeric pure 2-oxa-5,8-diazabicyclo (4.3.0)nonanes and process for their preparation | BAYER AG (DE) | 1993-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139504-B2 | Vanadium alkylidene complex, synthesis and use thereof | VDAC3, CDV3, CBR3 | PKM 80/4885HTT 1742/4885ALDH1A1 4675/4885 |
| US-12377407-B2 | Compositions and methods for visible-light-controlled ruthenium-catalyzed olefin metathesis | PPOX, CYBA, CYBB | PKM 4372/4885HTT 2745/4885ALDH1A1 1395/4885 |
| US-20240228519-A1 | VANADIUM ALKYLIDENE COMPLEX, SYNTHESIS AND USE THEREOF | VDAC3, CDV3, CBR3 | PKM 80/4885HTT 1742/4885ALDH1A1 4675/4885 |
| US-20250042854-A1 | IMINIUM SALTS WITH A BARRALENE RING, CORRESPONDING RUTHENIUM COMPLEXES, AND USES THEREOF | SQLE, SYMPK, FDFT1 | PKM 4697/4885HTT 2939/4885ALDH1A1 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.